Mahmut TÖBÜ, Filiz VURAL, Murat TOMBULOĞLU, Ayşe UYSAL, Fahri ŞAHİN, Güray SAYDAM, Melda ÖZKAN, Nur Akad SOYER

Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractorymultiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 andJanuary 2016 were screened. The patients were followed until March 2016 after CFZ treatment.Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47–76) years. The mediannumber of prior treatment lines was 3 (2–7). The median number of administered cycles of treatment for CFZ was 4 (1–10). The medianoverall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The mostcommon nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient diedbecause of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7–9) and 3(2–16) months, respectively. The median overall survival was 8 (0.5–33) months.Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreatedR/R-MM patients.

PDF

___

Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM-Int J Med 2007; 100: 635-640.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014; 64: 9-29.
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.
Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118: 4519-4529.
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
Kumar K, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Klein S, Lahuerta J, Laubach J, Lee J et al. Outcome of patients with myeloma relapsing after IMiD and bortezomib therapy: a multicenter study from the International Myeloma Foundation Working Group. Haematologica 2010; 95: 151.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology GroupNeurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13: 741-748.
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012; 158: 739-748.
Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 2017; 31: 107-114.
Nooka AK, Badros AZ, Patel P, McCulloch L, Lonial S, Kaufman JL. Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma. ASCO Meeting Abstracts 2012; 30: 8086. 16. Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014; 6: 87- 89.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicenter retrospective observational study. Br J Haematol 2016; 172: 89- 96.